Article Details
Retrieved on: 2022-08-25 06:08:23
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
AstraZeneca and MSD's Lynparza (olaparib) has been approved in Japan for the adjuvant treatment of patients with BRCA-mutated (BRCAm), ...
Article found on: news.cision.com
This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here